St. Jude ranks in top 10 of U.S. News Best Children’s Hospitals for Cancer

St. Jude Children’s Research Hospital was recognized as one of the top 10 pediatric cancer hospitals for the 17th straight year by U.S. News & World Report. Every year since 2008, the publication has evaluated about 100 hospitals with pediatric oncology programs and ranked the top 50 as part of its annual list of Best Children’s Hospitals.

Scientists identify genes linked to relapse in the most common form of childhood leukemia

Scientists from St. Jude Children’s Research Hospital, Seattle Children’s and the Children’s Oncology Group (COG) have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood cancer.

MD Anderson recognizes outstanding faculty

The University of Texas MD Anderson Cancer Center last night recognized over 100 faculty members at its annual Celebration of Faculty Excellence awards ceremony, acknowledging their compassionate care, exceptional contributions to their fields and the distinction they have brought to the institution.

MD Anderson Research Highlights: EHA 2024 Special Edition

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research, and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

MD Anderson Research Highlights for June 5, 2024

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

An anti-inflammatory curbs spread of fungi causing serious blood infections

Study finds that mesalamine, a common anti-inflammatory drug, can fight the fungus Candida albicans in the gut, potentially preventing the risk of invasive candidiasis in patients with blood cancers.

Awards totaling $2.6 Million Support Exploration of Therapeutic Strategy for Adult and Pediatric T-cell Acute Lymphoblastic Leukemia

Daniel Herranz Benito, PhD, PharmD, resident researcher at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, and associate professor of pharmacology and pediatrics at Rutgers Robert Wood Johnson Medical School, has received a total of $2.6M to support his research on acute lymphoblastic leukemia (ALL), an aggressive type of leukemia that affects both children and adults.

First in human trial of new drug raises hopes for patients with relapsed blood cancer

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia and Non-Hodgkin lymphoma whose disease has stopped responding to standard treatments.

Mount Sinai Launches Institute for Regenerative Medicine

Institute, including three new centers, will lead research to foster novel discoveries and explore new treatments for a range of diseases from leukemia to Alzheimer’s disease.

Scientists Create Most Powerful, Accurate Tool Yet to Research Deadliest Blood Cancer

Tisch Cancer Center scientists have developed unique models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. The models were described in a late-breaking abstract at the annual meeting of the American Association of Cancer Research and simultaneously published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.

Chula Makes Progress in “CAR T-Cell Therapy” Innovation: New Hope for Thai Lymphoma Cancer Patients

Chulalongkorn University, Thailand, and Nagoya University, Japan, in their collaboration to develop an immunotherapy method for curing cancer, reported on the progress of CAR T-cell immunotherapy innovation for treating cancer in leukemia and B-cell lymphoma patients, which can increase survival rates and reduce cancer recurrence.

Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.

Novel drug combinations and targeted therapies show promise for patients with leukemia

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting. These oral presentations highlight encouraging results to advance the use of targeted therapies and novel combinations in multiple types of leukemia, including high-risk and newly diagnosed acute myeloid leukemia (AML) in older and younger patients and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).

MD Anderson Research Highlights for September 28, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include an investigation into the efficacy of dexamethasone for dyspnea relief, a combination therapy for hairy cell leukemia, an analysis of RAS mutations and their prognostic value in acute myeloid leukemia (AML), a possible new combination therapy for basal-like breast cancer, and swallowing exercises to improve the quality of life for patients with head and neck cancer undergoing radiotherapy.

NCCN Annual Congress on Hematologic Malignancies™ Returns to In-Person October 14–15, 2022 in New York City

The 2022 NCCN Annual Congress on Hematologic Malignancies™ (#NCCNhem22) is taking place Friday, October 14–Saturday, October 15, 2022 in New York City. All live sessions will also stream remotely through a virtual event platform.

Scientists discover genes that affect the risk of developing pre-leukaemia

The discovery of 14 inherited genetic changes which significantly increase the risk of a person developing a symptomless blood disorder associated with the onset of some types of cancer and heart disease is published today in Nature Genetics. The finding, made in one of the largest studies of its kind through genetic data analysis on 421,738 people, could pave the way for potential new approaches for the prevention and early detection of cancers including leukaemia.

MD Anderson Research Highlights for June 29, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy response in breast cancer, integrated CRISPR screens to identify novel tumor suppressors, and a deeper knowledge of the immune tumor microenvironment in melanoma-derived brain metastases.

Roswell Park Expert to Present on Effectiveness of New Combination for Acute Myeloid Leukemia

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML), in a talk at the American Society of Clinical Oncology (ASCO) annual meeting 2022.

MD Anderson Research Highlights for May 4, 2022

Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.

New discoveries reveal how acute myeloid leukemia walks a fine line between growth and cell death

Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a study published in Molecular Cell on July 20, 2021. They describe a mechanism by which AML cells regulate a cancer-related protein, mutant IDH2, to increase the buildup of blood cancer cells—a distinguishing characteristic of the disease.